ARCHIVES

NCI Programs: New RAID Program Offers NCI Expertise In Drug Development

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

December 3, 2010

Xeloda As Effective As 5-FU/LV, Five-Year Survival Data Show

September 28, 2007

Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden

July 26, 2013

NCCTG Plans To Conduct Phase II Study Of Brostallicin Plus Cisplatin For mTNBC

April 30, 2010

House panel investigating NIH handling of tissue specimens.

June 24, 2005

Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic

May 30, 2014